51
|
Ledbetter O, Davis C. Clinical conversations: assessing the impact of training on patient experience. Physiotherapy 2019. [DOI: 10.1016/j.physio.2018.11.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
52
|
Green T, Davis C, Lambert R, Bird J. INCREASED REACTIVITY THRESHOLD IN PEANUT-ALLERGIC SUBJECTS TREATED WITH 12 MONTHS OF EPICUTANEOUS VIASKIN PEANUT. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
53
|
Greenhawt M, Carr W, Davis C, Lieberman J, Mustafa S, Green T, Gramme P, Lambert R, Fleischer D. SERUM BIOMARKERS OF IMMUNOMODULATION DURING PEANUT EPICUTANEOUS IMMUNOTHERAPY (EPIT) IN PEANUT-ALLERGIC SUBJECTS. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
54
|
Davis C, Sentell T, Pirkle C, Fernandes de Souza Barbosa J, Curcio C, Ylli A. Meeting Physical Activity Guidelines by Walking in Older Adults from Three-Middle Income Countries. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky212.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
55
|
Davis C, McCain J, Israel H, Choi D, Behrman D, Grewal N. Arthroscopy of Temporomandibular Joint Prosthesis, Preliminary Experience and Results. J Oral Maxillofac Surg 2018. [DOI: 10.1016/j.joms.2018.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
56
|
Alekseev O, Admire K, Brogdon J, Gorman B, Davis C, Vaskalis Z. Anti-tNASP antibodies as a diagnostic marker for malignant tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
57
|
Bauml J, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen R, Langer C. OA07.01 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
58
|
Chan E, Quinn C, Hirji I, Hillengass J, Anderson K, Oukessou A, Davis C. Alternative metrics for assessing clinical benefit with immunotherapy in oncology. Oncoimmunology 2018; 8:e1343774. [PMID: 31646068 DOI: 10.1080/2162402x.2017.1343774] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Revised: 06/08/2017] [Accepted: 06/12/2017] [Indexed: 01/09/2023] Open
Abstract
Therapies for cancer have traditionally been assessed with metrics such as the response rate, hazard ratio, or median survival. Such metrics have value in measuring the outcomes of conventional therapies, but may not be the most appropriate for new therapies. Immuno-oncology therapies offer a new approach to treating cancer by stimulating patients' immune systems to fight cancer. The value of these novel therapies has so far been assessed with traditional metrics, but the different ways in which immuno-oncology therapies work can mean the full value is not captured. Immuno-oncology therapies can produce longer survival times but this effect can be delayed or even preceded by an apparent phase of progression, which median survival or response rates may not reflect. This paper discusses a range of traditional and alternative metrics and their benefits or disadvantages in measuring the effects of immuno-oncology therapies, using examples of several novel drugs as case studies.
Collapse
|
59
|
Aggarwal A, Bernays S, Payne H, van der Meulen J, Davis C. Hospital Choice in Cancer Care: A Qualitative Study. Clin Oncol (R Coll Radiol) 2018; 30:e67-e73. [PMID: 29680734 DOI: 10.1016/j.clon.2018.03.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Revised: 03/14/2018] [Accepted: 03/19/2018] [Indexed: 10/17/2022]
Abstract
AIMS There is limited evidence about how patients respond to hospital choice policies, the factors that inform and influence patient choices or how relevant these policies are to cancer patients. This study sought to evaluate hospital choice policies from the perspective of men who received treatment for prostate cancer in the English National Health Service. MATERIALS AND METHODS Semi-structured interviews were undertaken with a purposive sample of 25 men across England. Fourteen men had chosen to receive treatment at a cancer centre other than their nearest. Interviews were recorded and analysed concurrently with data collection. RESULTS Men highlight that the geographical configuration of specialist services, the perceived urgency of the condition and the protocolisation of treatment pathways all limit their choice of a specialist treatment centre. Diseases such as cancer appear not to be well suited to the patient choice model, given the lack of hospital-level outcome data. Men instead use proxy measures of quality, leaving them vulnerable to influence by marketing and media reports. Men wishing to consider other treatment centres need to independently collect and appraise complex treatment-related information, which creates socioeconomic inequities in access to treatments. A positive impact of the choice agenda is that it enables patients to 'exit care' not meeting their expectations. DISCUSSION Policy makers have failed to consider the organisational, disease-specific and socio-cognitive factors that influence a patient's ability to choose their cancer treatment provider. Valid comparative hospital-level performance information is required to guide patients' choices, otherwise patients will continue to depend on informal sources, which will not necessarily improve their health care outcomes.
Collapse
|
60
|
Rickard C, Marsh N, Larsen E, Corley A, Spooner A, Fraser J, Davis C, Lepelaar S, Long D, Roberts B, Baker S, Gill F, Gowardman J, Murgo M, Alexandrou E, Palermo A, Regli A, McGrail M, Runnegar N. Intravenous administration set (infusion tubing) replacement after 4 or 7 days is equally effective to prevent bloodstream infections (RSVP trial). Aust Crit Care 2018. [DOI: 10.1016/j.aucc.2017.12.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
61
|
Justice SMM, Britt J, Jr. MM, Greene M, Davis C, Koch B, Duckett S, Jesch E. Predictions of Lean Meat Yield in Lambs Using Dexa and Chemical Analyses Proximate. MEAT AND MUSCLE BIOLOGY 2018. [DOI: 10.22175/rmc2018.162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
62
|
Forster KI, Davis C, Schoknecht C, Carter R. Masked priming with graphemically related forms: Repetition or partial activation? ACTA ACUST UNITED AC 2018. [DOI: 10.1080/14640748708401785] [Citation(s) in RCA: 166] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Form-priming occurs when a prime that is graphemically similar to the target word facilitates processing of the target. In an activation model (such as Morton's logogen model), such an effect can be interpreted as a partial-activation effect. A prime that shares letters with the target must inevitably produce activation in the detectors for both the prime and the target. Alternatively, form-priming could be seen as a special case of repetition-priming, in which the prime actually accesses the entry for the target. It is shown that masked-priming effects in the lexical decision task can be obtained for graphemically related pairs such as bontrast-CONTRAST, but not for four-letter pairs such as bamp-CAMP. It is suggested that the priming effect is controlled by neighbourhood density, short words usually having many neighbours, long words having very few. This hypothesis is supported by the finding that form-priming does occur for four-letter words if the prime and target are drawn from low-density neighbourhoods. For a partial-activation theory, an inhibitory mechanism that is sensitive to the number of prime-neighbours is required to explain the results. Of the several versions of a repetition account considered, the “best match” hypothesis appears to be the most promising: this assumes that priming is limited to the stimulus that best matches the prime. It is also shown that prime-target pairs that are related in form and meaning (e.g. made-MAKE) produce the same priming effect as identical pairs, as predicted by a repetition account that assumes a common entry underlying both forms.
Collapse
|
63
|
Davies M, Alborough R, Jones L, Davis C, Williams C, Gardner DS. Mineral analysis of complete dog and cat foods in the UK and compliance with European guidelines. Sci Rep 2017; 7:17107. [PMID: 29215022 PMCID: PMC5719410 DOI: 10.1038/s41598-017-17159-7] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Accepted: 11/17/2017] [Indexed: 12/05/2022] Open
Abstract
Mineral content of complete pet food is regulated to ensure health of the companion animal population. Analysis of adherence to these regulatory guidelines has not been conducted. Here, mineral composition of complete wet (n = 97) and dry (n = 80) canine and feline pet food sold in the UK was measured to assess compliance with EU guidelines. A majority of foods complied with ≥8 of 11 guidelines (99% and 83% for dry and wet food, respectively), but many failed to provide nutritional minimum (e.g. Cu, 20% of wet food) or exceeded nutritional maximum (e.g. Se, 76% of wet food). Only 6% (6/97) of wet and 38% (30/80) of dry food were fully compliant. Some foods (20–30% of all analysed) had mineral imbalance, such as not having the recommended ratio of Ca:P (between 1:1 to 2:1). Foods with high fish content had high levels of undesirable metal elements such as arsenic. This study highlights broad non-compliance of a range of popular pet foods sold in the UK with EU guidelines (94% and 61% of wet and dry foods, respectively). If fed exclusively and over an extended period, a number of these pet foods could impact the general health of companion animals.
Collapse
|
64
|
Cassius C, Davis C, Valeyrie-Allanore L, Bravard P, Carre-Gislard D, Modiano P, Wolkenstein P, Chosidow O. Toxidermies par erreur de délivrance médicamenteuses : rapport de cas et étude de la pharmacopée française. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
65
|
Yeh C, Su H, Martinez C, Hunt R, Freeman A, Shah N, Davis C. P287 The big masquerade: atopy as the presenting symptom of DOCK8 deficiency. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
66
|
Wootten B, Yoder J, Walker C, Davis C, Sulava E, Zarow G, Loomis A. 355 A Trial of Terlipressin Compared to Small Volume Resuscitation in a Swine (Sus scrofa) Model of Uncontrolled Hemorrhage and Severe Hemorrhagic Shock. Ann Emerg Med 2017. [DOI: 10.1016/j.annemergmed.2017.07.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
67
|
Burnsides C, Hill J, Davis C, Moorman M, O'Mara M, Spalding C. 342 Beyond the Denver Criteria: How Enhanced Blunt Cerebrovascular Injury Screening Changes Patient Outcomes and Captures a Previously Missed Population. Ann Emerg Med 2017. [DOI: 10.1016/j.annemergmed.2017.07.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
68
|
Bush D, Teichman S, Do S, Grove R, Davis C, Slater J. Long-Term Quality of Life Outcomes of Proton Beam PBI Compared With Photon Whole Breast Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
69
|
Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol 2017; 28:1738-1750. [PMID: 28453615 PMCID: PMC5834015 DOI: 10.1093/annonc/mdx110] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs, including those that had been previously appraised but not approved by NICE (National Institute for Health and Care Excellence). After 1.3 billion GBP expenditure, a UK parliamentary review in 2016 rationalized the CDF back into NICE. METHODS This paper analyses the potential value delivered by the CDF according to six value criteria. This includes validated clinical benefits scales, cost-effectiveness criteria as defined by NICE and an assessment of real-world data. The analysis focuses on 29 cancer drugs approved for 47 indications that could be prescribed through the CDF in January 2015. RESULTS Of the 47 CDF approved indications, only 18 (38%) reported a statistically significant OS benefit, with an overall median survival of 3.1 months (1.4-15.7 months). When assessed according to clinical benefit scales, only 23 (48%) and 9 (18%) of the 47 drug indications met ASCO and ESMO criteria, respectively. NICE had previously rejected 26 (55%) of the CDF approved indications because they did not meet cost-effectiveness thresholds. Four drugs-bevacizumab, cetuximab, everolimus and lapatinib-represented the bulk of CDF applications and were approved for a total of 18 separate indications. Thirteen of these indications were subsequently delisted by the CDF in January 2015 due to insufficient evidence for clinical benefit-data which were unchanged since their initial approval. CONCLUSIONS We conclude the CDF has not delivered meaningful value to patients or society. There is no empirical evidence to support a 'drug only' ring fenced cancer fund relative to concomitant investments in other cancer domains such as surgery and radiotherapy, or other noncancer medicines. Reimbursement decisions for all drugs and interventions within cancer care should be made through appropriate health technology appraisal processes.
Collapse
|
70
|
Juby A, Davis C, Minimaana S. COMPARING SUBJECTS EWGSOP SARCOPENIC STATUS AND THEIR CLINICAL FRAILTY SCALE LEVEL. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
71
|
Gopal A, Levy R, Houot R, Patel S, Hatake K, Popplewell L, Chen Y, Davis C, Huang B, Cesari R, Thall A, Woolfson A, Bartlett N. A PHASE I STUDY OF UTOMILUMAB (PF-05082566), A 4-1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+
NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_127] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
72
|
Timoshchuk M, Dekker P, Davis C, Laramore G, Dillon J. Neutron radiation efficacy when treating salivary gland malignancies. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
73
|
Keshishian E, Ajrawat H, Massis K, Davis C, Hoots G, Rojas H, Kumar A, Meader S. Clinical utility of image-guided biopsy in diagnosis and management of vertebral osteomyelitis: A retrospective cohort study. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.1148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
74
|
Husson J, Stafford K, Bromberg J, Haririan A, Sparkes T, Davis C, Redfield R, Amoroso A. Association Between Duration of Human Immunodeficiency Virus (HIV)-1 Viral Suppression Prior to Renal Transplantation and Acute Cellular Rejection. Am J Transplant 2017; 17:551-556. [PMID: 27458893 DOI: 10.1111/ajt.13985] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Revised: 07/05/2016] [Accepted: 07/19/2016] [Indexed: 01/25/2023]
Abstract
Renal transplant has become an important option for human immunodeficiency virus (HIV)-infected patients with end-stage renal disease; however, these patients experience a high rate of acute cellular rejection (ACR). Guidelines do not currently exist for the optimal duration of viral suppression prior to transplantation. In a retrospective cohort analysis of 47 HIV-infected renal transplant recipients, we compared the rate of ACR between patients based on the length of time of viral suppression prior to transplantation. Of the patients who achieved viral suppression for >6 months but less than 2 years prior to transplantation (n = 15), 60% experienced ACR compared to 41% of patients suppressed at least 2 years or more (n = 32) prior to transplant (p = 0.21). Patients suppressed <2 years experienced ACR at 2.48 times the rate of those suppressed 2 years or longer. Induction immunosuppression, HLA mismatch and panel-reactive antibodies (PRAs) did not significantly differ between the two groups.
Collapse
|
75
|
Davis C, Seddighi R, Cox S, Sun X, Egger C, Doherty T. Effect of fentanyl on the minimum infusion rate of propofol preventing movement in dogs. Vet Anaesth Analg 2017. [DOI: 10.1016/j.vaa.2016.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|